Patents Examined by Mark V Stevens
  • Patent number: 11510943
    Abstract: The present invention relates to a chemotherapeutic agent comprising a combination of alexidine dihydrochloride and sodium pentaborate pentahydrate. The chemotherapeutic agent includes 2.9 mg alexidine dihydrochloride compound and 2.5 mg sodium pentaborate pentahydrate compound, and is obtained by adding 0.5 ml dimethylsulfoxide compound into the alexidine dihydrochloride compound. Upon injecting them to the media containing healthy cells and cancer cells, their effects on cell viability were observed. In accordance with the obtained results; it was observed that when alexidine dihydrochloride solution at concentrations not harming healthy cells is combined with sodium pentaborate pentahydrate, pancreatic cancer cell viability decreased 10% more compared to use of alexidine dihydrochloride alone, and it was realized that this combination can be used as a chemotherapeutic agent for treatment of pancreatic cancer.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: November 29, 2022
    Assignee: YEDITEPE UNIVERSITESI
    Inventors: Fikrettin Sahin, Ezgi Kasikci, Esra Aydemir Coban
  • Patent number: 11504335
    Abstract: The presently-disclosed subject matter relates to compositions of dual layer encapsulated cells, dual layer encapsulated stem cells. The presently-disclosed subject matter further relates to methods for improving retention of cells in vivo at a site of injury.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: November 22, 2022
    Assignee: University of Kentucky Research Foundation
    Inventors: Anuhya Gottipati, Irina Kalashnikova, Ahmed Abdel-Latif, Bradley J. Berron
  • Patent number: 11497695
    Abstract: Zinc oxide powder of the present invention contains zinc oxide particles, in which primary particles of the zinc oxide particles have a minor axis of 35 nm or more and 350 nm or less and have a Heywood diameter of 35 nm or more and 400 nm or less, and a coefficient of variation of a number distribution of the Heywood diameters of the primary particles of the zinc oxide powder is 50% or less.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: November 15, 2022
    Assignee: SUMITOMO OSAKA CEMENT CO., LTD.
    Inventors: Gaku Fujihashi, Shingo Hosoda, Kenichiro Nishida, Syunsuke Suma
  • Patent number: 11497766
    Abstract: Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: November 15, 2022
    Assignee: CXL OPHTHALMICS, LLC
    Inventors: Roy S. Rubinfeld, Raymond A. Hartman, Sandy T. Feldman
  • Patent number: 11497710
    Abstract: The present embodiments provide compositions, methods and kits for the treatment of ocular conditions or maladies affecting the back of the eye, e.g., the retina.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: November 15, 2022
    Assignee: CHIBI, INC.
    Inventors: Vernon G. Wong, Glenn T. Huang
  • Patent number: 11491143
    Abstract: The present invention relates to methods and compositions for the treatment and prophylaxis of pulmonary arterial hypertension (PAH) in a human subject in need of such treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation of a composition comprising rapamycin or a prodrug or derivative thereof.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: November 8, 2022
    Assignee: AI Therapeutics, Inc.
    Inventors: Thomas Armer, Lawrence S. Melvin, Jr., Jonathan M. Rothberg, Henri Lichenstein
  • Patent number: 11491109
    Abstract: The present invention provides novel, solid or liquid pharmaceutical preparations comprising a basic or neutral, low molecular weight active pharmaceutical ingredient and the polymer Eudragit® EPO, optionally together with additional pharmaceutically acceptable excipients. The present preparations are for oral or topical administration.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: November 8, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jochem Alsenz, Martin Kuentz, Alfred Ross, Wiebke Svea Saal, Nicole Wyttenbach
  • Patent number: 11491097
    Abstract: The present invention provides a simple method for producing a medical/cosmetic sheet that is excellent in adhesion to skin or the like and sense of wearing, and is capable of releasing a functional component gradually and supplying it continuously to a treatment area or the like, and a medical/cosmetic sheet produced by this production method. Provided is a method for producing a medical/cosmetic material including a step of shaping a raw material containing a water-soluble salt of a first polyanionic polysaccharide having a viscosity-average molecular weight of 10,000 or lower, and a water-soluble salt of a second polyanionic polysaccharide having a viscosity-average molecular weight of 50,000 or higher, and thereby obtaining a water-soluble shaped body. A medical/cosmetic material produced by this production method is also provided.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: November 8, 2022
    Assignee: DAINICHISEIKA COLOR & CHEMICALS MFG. CO., LTD.
    Inventor: Yasuyuki Isono
  • Patent number: 11484527
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Grant
    Filed: December 8, 2021
    Date of Patent: November 1, 2022
    Assignee: Allergan Holdings Unlimited Company
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
  • Patent number: 11484615
    Abstract: The use of compositions including two or more cucurbiturils in counteracting malodour in a moist environment. The two or more cucurbiturils are selected from CB[5], CB [6], CB [7] and CB[8]. Also provided is a method for counteracting malodour in a moist environment, including application of a composition including a mixture of two or more cucurbiturils selected from CB[5], CB[6], CB[7] and CB[8].
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: November 1, 2022
    Assignee: AQDOT LIMITED
    Inventors: Roger Coulston, Alexander Tanner, Jose Martinez-Santiago
  • Patent number: 11478431
    Abstract: Exemplary embodiments of the disclosure may be drawn to ingestible delivery devices. An ingestible delivery device may include a first compartment and a second compartment. A lipase may be contained within the first compartment, and a fat may be contained within the second compartment. The first compartment may be sealed from the second compartment prior to exposure to a trigger, preventing the lipase and the fat from contacting each other, and at least one of the first compartment or the second compartment may at least partially rupture upon exposure to the trigger, allowing the lipase and the fat to contact each other.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: October 25, 2022
    Assignee: Alcresta Therapeutics, Inc.
    Inventors: Eric First, David Widom
  • Patent number: 11471412
    Abstract: Disclosed are nanoparticles and nanogel drug compositions and the use thereof for treating age-related macular degeneration.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: October 18, 2022
    Assignee: University of South Florida
    Inventors: Vijaykumar Bhadabhai Sutariya, Priyanka Sureshbhai Bhatt, Vipul B. Amin, Srinivas M. Tipparaju
  • Patent number: 11464760
    Abstract: The present invention relates to frigostable compositions suitable for iontophoretic transdermal delivery of a triptan compound that includes: a salt of a triptan compound, preferably sumatriptan succinate, a polyamine, one or more dicarboxylic acids, 0.5 to 10.0 wt.-% (based on the total weight of the composition) of one or more monocarboxylic acids, and water or an aqueous solvent mixture. The invention further relates to the use of the composition as an integral component of an iontophoretic patch, preferably as an anodic reservoir of the patch.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: October 11, 2022
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Michael Linn, Christoph Schmitz, Hanshermann Franke
  • Patent number: 11458081
    Abstract: Described herein are low pH, high water, personal care compositions providing an acceptable level of micropreservation. Methods of making and using these compositions are also described.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: October 4, 2022
    Assignee: Colgate-Palmolive Company
    Inventors: Paloma Pimenta, Farrah Syed, Jesse Reed
  • Patent number: 11452710
    Abstract: The micronutrient and plant extract composition comprises of a vitamin C, vitamin A (?-carotene), vitamin E, vitamin D3, vitamin K2, folic acid, calcium, magnesium, boron, horsetail extract, zinc, potassium, copper, methylsulfonylmethane (MSM) and stinging nettle extract and in combination it is used for treating, and reversing bone demineralization. The micronutrient and plant extract composition when administered to mammal with or without bone disease strengthens and helps in bone mineralization process. The composition can be used as a preventive dose for bone demineralization in human.
    Type: Grant
    Filed: February 17, 2022
    Date of Patent: September 27, 2022
    Inventor: Matthias W Rath
  • Patent number: 11446218
    Abstract: A method of reducing the appearance of hyperpigmented skin is disclosed. The method can include topically applying to hyperpigmented skin a composition comprising an aqueous and/or glycerin extract of Rhododendron ferrugineum leaf to reduce melanocyte pigmentation in the skin.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: September 20, 2022
    Assignee: MARY KAY INC.
    Inventor: David Gan
  • Patent number: 11439593
    Abstract: The present invention relates to a novel pharmaceutically active composition which is able to permeate into the deeper layers of the skin and the keratin sheets of nails. The composition is a microemulsion comprising at least an alcohol ethoxysulfate, an ethoxylated glyceryl fatty acid ester, and an ethoxylated sorbitol or sorbitol anhydride fatty acid ester. The composition may optionally comprise further additives like emollients, substances for hardening a nail, or substances for enhancing nail growth. The composition is particularly suitable for treating fungal infections of the skin or nails, such as athlete's foot and onychomycosis. The composition is also suitable for treating inflammatory skin diseases, such as psoriasis and atopic eczema.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: September 13, 2022
    Assignee: NCP NewCare Products GmbH
    Inventor: Volker Gustav Adolf Krainbring
  • Patent number: 11439599
    Abstract: The invention relates to a scored tablet (1) comprising a convex upper face (2), an at least partially concave lower face (3) and a side wall (4) extending between the upper and lower faces; two score grooves (5, 6) are formed in the concave lower face, said grooves being perpendicular to one another and continuous with score slits (8, 9, 10, 11) located in the side wall.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: September 13, 2022
    Assignee: CEVA SANTE ANIMALE
    Inventors: Nadège Mallo, Philippe Jolivet, Mickael Venel, Rosita Garcia
  • Patent number: 11439627
    Abstract: The present invention relates to a pharmaceutical composition or a kit comprising, a first substance capable of raising intracellular cAMP levels, and a second substance capable of modulating intracellular calcium concentration. Likewise, the present invention relates to methods of treating patients suffering from autism spectrum disorder (ASD) phenotype 1 by administering an effective amount of a substance capable of raising intracellular cAMP levels and, optionally, an effective amount of a substance capable of modulating intracellular calcium concentration.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: September 13, 2022
    Assignee: Stalicla S.A.
    Inventor: Lynn Durham
  • Patent number: 11433084
    Abstract: The present invention relates to a process for preparation of a water-insoluble steroid composition by moist heat sterilization. The invention particularly relates to a process for preparation of a water-insoluble steroid composition comprising moist heat sterilization or autoclaving of an aqueous slurry of methylprednisolone acetate in the presence of a specified quantity of polysorbate. The suspensions prepared by using the current invention exhibited good physical and chemical stability. Compositions related thereto are also disclosed.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: September 6, 2022
    Assignee: Somerset Therapeutics LLC
    Inventors: Rahul Kalhapure, Prem Sagar Akasapu, Veerappan Subramanian, Ilango Subramanian